Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Literature
1.
George SL (2016) Research misconduct and data fraud in clinical trials: prevalence and causal factors. Int J Clin Oncol. 21(1):15–21CrossRefPubMed
2.
3.
Wiwanitkit V (2015) Letter to the editor: plagiarism screening by the journal: is there still any pitfall? Account Res. 22(3):198–199CrossRefPubMed
4.
Wiwanitkit V, Qu S (2014) Open access publication, journal policy, and scientific community. Am J Med 127(5):e13CrossRefPubMed
Metadata
Title
Research misconduct and data fraud in clinical trials
Author
Viroj Wiwanitkit
Publication date
01-12-2016
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 6/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-0990-0

Other articles of this Issue 6/2016

International Journal of Clinical Oncology 6/2016 Go to the issue

Original Article

Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma

Original Article

Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass

Original Article

Microdissection testicular sperm extraction in Japanese patients with persistent azoospermia after chemotherapy

Original Article

Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab

Original Article

Screening rate for hepatitis B virus infection in patients undergoing chemotherapy in Japan

Original Article

The value of circulating CYFRA21-1 expression in patients with nasopharyngeal carcinoma: a study of 529 subjects
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits